Enliven Therapeutics (ELVN) Capital Expenditures (2019 - 2025)
Enliven Therapeutics' (ELVN) quarterly Capital Expenditures came in at $158000.0 in Q3 2025, up 618.18% year-on-year from $22000.0 in Q3 2024, and up 890.0% quarter-over-quarter from -$20000.0 in Q2 2025.
Enliven Therapeutics (ELVN) Capital Expenditures (2019 - 2025) Analysis & Trends
Enliven Therapeutics has disclosed Capital Expenditures across 7 years of filings, most recently posting $158000.0 for Q3 2025.
- Capital Expenditures for Q3 2025 came in at $158000.0, up 618.18% year-over-year; the trailing twelve-month figure through Mar 2026 was $138000.0 (up 213.64% YoY), and the FY2025 annual result was $158000.0, up 259.09% from the prior year.
- Capital Expenditures came in at $158000.0 for Q3 2025 at Enliven Therapeutics, up from -$20000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $303000.0 in Q2 2022 to a low of -$31000.0 in Q2 2023.
- The 5-year median for Capital Expenditures is $20000.0 (2024), against an average of $65000.0.
- Across the five-year window, Capital Expenditures jumped 1516.67% in 2022 and slumped 1100.0% in 2025, its largest moves.
- Enliven Therapeutics' Capital Expenditures stood at $12000.0 in 2021, then surged by 741.67% to $101000.0 in 2022, then slumped by 86.14% to $14000.0 in 2023, then surged by 57.14% to $22000.0 in 2024, then soared by 618.18% to $158000.0 in 2025.
- The last three Capital Expenditures figures came in at $158000.0 (Q3 2025), -$20000.0 (Q2 2025), and $20000.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 133.40 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -63,220.27 |
| 10 | Enliven Therapeutics | 2.32 Bn | 2.32 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 158,000.00 |
| Sep 30, 2025 | 158,000.00 |
| Jun 30, 2025 | -20,000.00 |
| Jun 30, 2025 | -20,000.00 |
| Mar 31, 2025 | 20,000.00 |
| Mar 31, 2025 | 20,000.00 |
| Sep 30, 2024 | 22,000.00 |
| Sep 30, 2024 | 22,000.00 |
| Jun 30, 2024 | 2,000.00 |
| Jun 30, 2024 | 2,000.00 |
| Mar 31, 2024 | 20,000.00 |
| Mar 31, 2024 | 20,000.00 |
| Dec 31, 2023 | 14,000.00 |
| Dec 31, 2023 | 14,000.00 |
| Sep 30, 2023 | 135,000.00 |
| Sep 30, 2023 | 135,000.00 |
| Jun 30, 2023 | -31,000.00 |
| Jun 30, 2023 | -31,000.00 |
| Mar 31, 2023 | 31,000.00 |
| Mar 31, 2023 | 31,000.00 |